Skip to main content

Project summary

Working in partnership with the Garvan Institute, we apply our omic technology to deeply-phenotyped cohorts of patients with liver and muscle insulin resistance to guide targeted type 2 diabetic therapy. We have identified signatures of hepatic insulin resistance and of skeletal muscle insulin resistance, which we will use to guide therapy using medications that target either of these organs. We are now testing whether our signatures of liver insulin resistance predict response to treatment with metformin, the first agent in the type 2 diabetes treatment algorithm that targets the liver.

HRI breakthrough drug for coronavirus

Read full article